Latest Breaking News On - Dustin sjuts - Page 1 : comparemela.com

Health Care Notes: Revance announces 2023 revenue jump, Q4 results

Also: Meharry lands clinical trial outreach grant; Sarah Cannon Research Institute announces partnership with AstraZeneca

Vanderbilt universityUnited statesMeharry medical collegeDee anna smithDustin sjutsEli richardsonRevance botoxMark foleyAbbvie allerganDiaspora human genomics instituteYale medical schoolMorehouse school of medicineVanderbilt university medical centerNashville sarah cannon research instituteEquitable breakthroughs in medicine developmentSarah cannon research institute

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

28.02.2024 - Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update. Financial Highlights Total revenue for the fourth quarter 2023 was $69.8 .

United statesMarkj foleyMark foleyLang schwarzDustin sjutsTobin schilkeDavid hollanderViatris incUs centers for medicare medicaid servicesRevance therapeutics incDecision resources group aesthetics injectables botulinum toxinSecurities exchangeDrug administrationAmerican academy of neurologyExchange commissionDecision resources group market analysis

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023.

Dustin sjutsMarkj foleyViatris incPeptide exchange technologyExchange commissionSecurities exchangeRevance therapeutics incDecision resources group aesthetics injectables botulinum toxinDecision resources group market analysisRevance therapeuticsChief executive officerMarketing approvalErica jordanChief commercial officerFinancial outlookBoxed warning

Revance Therapeutics Shares Slide on Guidance Shortfall

By Colin Kellaher Revance Therapeutics shares fell more than 15% on Monday after the biotechnology company's guidance fell short of Wall Street's.

Dustin sjutsColin kellaherWall streetArticle normalBiotechnology servicesHealthcare life sciencesFinancial performanceShare price movement disruptionsCorporate industrial newsContent typesFactiva filtersC amp ampe exclusion filterC amp ampe industry news filterRevance therapeuticsShare price movementIndustrial news

Revance Therapeutics Stock: Not Even Daxxify Can Treat Investor Frown Lines (NASDAQ:RVNC)

Revance Therapeutics Stock: Not Even Daxxify Can Treat Investor Frown Lines (NASDAQ:RVNC)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesLauren silvernailIpsen dysportDustin sjutsKlaus vedfelt digitalvisionDan browneMark foleySupernus pharmaceuticalsPresent dayFights for approval of frown lineRevance therapeuticsDaxibotulinumtoxina topical gelChief executive officerChief financial officerChief business officer lauren silvernailBiological license application